Sermaglutide
- CasNo：910463-68-2
- Molecular Formula：C187H291N45O59
- Purity：
- Molecular Weight：4113.57754
Product Details
Sermaglutide 910463-68-2 GMP Manufacturer supply high quality Sermaglutide (CAS 910463-68-2), in stock, factory directly supply to clients, lower prices, more competitiveness.
What is the Sermaglutide ?
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a long elimination half-life, allowing subcutaneous (sc) administration once per week, while it's Molecular Formula is C187H291N45O59. Semaglutide injection is in a class of medications called incretin mimetics. It works by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Semaglutide is a GLP-1 analogue shown to reduce energy intake, reduce hunger and increase feelings of satiety and fullness.
What is the CAS number for Sermaglutide ?
The CAS number of Sermaglutide is 910463-68-2.
More information of Sermaglutide 910463-68-2 are:
|
Synonyms |
Sermaglutide |
|
CAS Number |
910463-68-2 |
|
Molecular Formula |
C187H291N45O59 |
|
Molecular Weight |
4113.57754 |
|
PSA |
1646.18000 |
|
LogP |
5.44520 |
What is Sermaglutide (910463-68-2) used for?
Oral semaglutide, the first oral GLP-1RA, has recently been approved for clinical use, based on the results of the randomized, Phase 3a Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) clinical trials. Semaglutide, sold under the brand name Ozempic among others, is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management. Semaglutide injection (Wegovy) is used along with an individualized low-calorie, low-fat diet and exercise program to help with weight loss in overweight adults who may also have high blood pressure, diabetes, or high cholesterol. Semaglutide is a potent long-acting glucagon-like peptide-1 (GLP-1) analogue that requires once-weekly administration.
Articles related to Sermaglutide:
|
Article |
Source |
|
Semaglutide for the treatment of overweight and obesity: A review ,Diabetes, Obesity and Metabolism, Volume25, Issue1 January 2023 Pages 18-35 |
The Semaglutide Treatment Effect in People with obesity (STEP) clinical trial programme is evaluating once-weekly subcutaneous semaglutide 2.4 mg (a glucagon-like peptide-1 analogue) in people with overweight or obesity. |
|
Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme ,Diabetes, Obesity and Metabolism, Volume22, Issue8 August 2020 Pages 1263-1277 |
The results of the PIONEER programme suggest that oral semaglutide is efficacious and well tolerated for glycaemic control of T2D. The availability of oral semaglutide may help to broaden treatment choice and facilitate adoption of earlier GLP-1RA treatment in the paradigm of T2D management. |
|
Once-weekly semaglutide in adolescents with obesity ,The New England Journal of Medicine 2022; 387:2245-2257 |
Semaglutide is a glucagon-like peptide-1 analogue that induces weight loss by decreasing appetite, thereby improving control of eating and reducing energy intake. Among adolescents with obesity, once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone. |
Sermaglutide 910463-68-2 GMP Manufacturer with Best Price
Qingdao Beluga Import and Export Co., LTD is a GMP Manufacturer of Sermaglutide . You can buy high quality, best price Sermaglutide 910463-68-2 here. Contact us.
